Peter Kaiser, MD

A panel of ophthalmologists discuss how retinal disease management has evolved in the past decade and continues to change with advancements in diagnostics and therapies.

A panel of ophthalmologists discuss how retinal disease management has evolved in the past decade and continues to change with advancements in diagnostics and therapies.

Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.

An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.

Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.

Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.

Dr Peter Kaiser outlines approval process of biosimilars and highlights key differences from approval process of reference products.

An ophthalmology expert provides an overview of biosimilars and their potential in ophthalmology practices.